Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

3 API Suppliers, 3 Listed Suppliers

3 API Suppliers
3 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

7 FDF Dossiers, 4 FDA Orange Book, 3 Listed Dossiers

7 FDF Dossiers
4 FDA Orange Book
3 Listed Dossiers

MARKET PLACE

1 APIs

marketPlace
1 APIs

Centrient Rosuvastatin Zinc Popup

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as:

Molecular Formula

C₄₄H₅₆F₂N₆O₁₂S₂Zn+₂

Molecular Weight

1028.5 g/mol

InChI Key

KUQHZGJLQWUFPU-BGRFNVSISA-N

1 2D Structure

Rosuvastatin Zinc

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

zinc;(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

2.1.2 InChI

InChI=1S/2C22H28FN3O6S.Zn/c2*1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h2*5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;;+2/b2*10-9+;/t2*16-,17-;/m11./s1

2.1.3 InChI Key

KUQHZGJLQWUFPU-BGRFNVSISA-N

2.1.4 Canonical SMILES

CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.CC(C)C1=NC(=NC(=C1C=CC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C.[Zn+2]

2.1.5 Isomeric SMILES

CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.CC(C1=NC(=NC(=C1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)C2=CC=C(C=C2)F)N(S(=O)(=O)C)C)C.[Zn+2]

2.2 Create Date

2012-03-21

3 Chemical and Physical Properties

Molecular Formula	C₄₄H₅₆F₂N₆O₁₂S₂Zn+₂
Molecular Weight	1028.5 g/mol
Hydrogen Bond Donor Count	6
Hydrogen Bond Acceptor Count	20
Rotatable Bond Count	20
Exact Mass	1026.265712 g/mol
Monoisotopic Mass	1026.265712 g/mol
Topological Polar Surface Area	299 A^2
Heavy Atom Count	67
Formal Charge	2
Complexity	767
Isotope Atom Count	0
Defined Atom Stereocenter Count	4
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	2
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

4 Drug and Medication Information

4.1 Drug Information

1 of 2
Drug Name	Rosuvastatin zinc
Active Ingredient	Rosuvastatin zinc
Dosage Form	Tablet
Route	oral
Strength	5mg; 10mg; 40mg; 20mg
Market Status	Tentative Approval
Company	Watson Labs

2 of 2
Drug Name	Rosuvastatin zinc
Active Ingredient	Rosuvastatin zinc
Dosage Form	Tablet
Route	oral
Strength	5mg; 10mg; 40mg; 20mg
Market Status	Tentative Approval
Company	Watson Labs